Title
Category
Credits
Event date
Cost
Out of the Dark, Into the Light: Illuminating Modern Strategies for the Detection and Treatment of Bipolar Depression
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
OverviewUp to 80% of patients with bipolar disorder (BD) initially present with depression. However, without experience of or insight into their mania, these patients are easily misdiagnosed with major depressive disorder (MDD) or other psychiatric conditions. Once an accurate diagnosis is obtained, ensuring appropriate treatment of BD depression is essential, but a variety of misconceptions and outdated strategies significantly complicate this process.
Thinking Through ARIA: A Case-Based Exploration of Recognition, Evaluation, and Reporting of Novel Imaging Events of Alzheimer's Therapeutics
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionWith recent approvals of amyloid-targeting therapies (ATTs) for patients with mild cognitive impairment (MCI) and early Alzheimer’s disease (AD) neurobiology, AD management is facing an imminent paradigm shift.
Individualizing Narcolepsy: Using Clinical Evidence and Patient Factors to Improve Diagnosis and Optimize Therapeutic Management
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionSleep experts Drs. Lynn Marie Trotti, Asim Roy, and Anne Marie Morse offer a comprehensive approach to narcolepsy treatment, embracing recent pharmacological advancements (e.g., pitolisant, solriamfetol, low sodium oxybate [LXB], once nightly sodium oxybate [ON-SXB]). Learners will explore how to tailor individual treatment regimens by moving beyond traditional focuses like cataplexy and excessive daytime sleepiness to address newer concerns such as disrupted nighttime sleep and autonomic dysfunction.
Stronger Together: Leveraging Evidence-Based Patient Collaboration and Treatment Strategies to Streamline Success in Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionWith the variety of possible risk factors, presentations, impacts, and preferences among individual patients with multiple sclerosis (MS), it has been well-established that every case of MS is unique. It is perhaps because of this that a collaborative, shared decision-making (SDM) approach has emerged as the preferred model of clinical care. However, in an age of over 20 FDA-approved disease modifying therapies (DMTs) and continuously evolving strategies for monitoring therapeutic response, the scope of shared clinical decisions is increasingly broad.
Unlocking the Alzheimer’s Brain: How Radiological Tools and Biomarkers Hold the Key to Early Diagnosis and Decision-Making
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionThe age of disease-modifying therapy in Alzheimer’s disease (AD) is now a reality with one amyloid beta targeting therapy (ATT) approved and another under regulatory review. Both agents require early diagnosis and therapeutic initiation to exert their effects. Not only is imaging a key component for the diagnosis of AD and to determine ATT eligibility, but all ATTs have the potential for unique adverse effects called amyloid-related imaging abnormalities (ARIA), necessitating frequent MRI monitoring and evaluation.
When the Default is Not Enough: An Emergency Medicine Clinician's Guide to Novel Amyloid-Related Imaging Abnormalities in Alzheimer's Disease
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
 
Pay It Forward: Bridging the Gaps Between Payers and Providers to Get the Medication Your Patient Needs When They Need It for Narcolepsy and Idiopathic Hypersomnia
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionPatients with narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH) have a diverse range of clinical presentations and therapeutic needs that complicate the process of diagnosis and management. Although significant advancements have been made with the recent approval of several pharmacologic agents specifically indicated for these disorders, the pursuit of insurance authorization for these strategies often leads to obstacles that limit optimal clinical implementation and corresponding patient outcomes.
Following a Moving Target: Current and Emerging Strategies for the Prevention and Management of COVID-19 in Patients with Multiple Sclerosis
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$0.00
Program DescriptionAs our understanding of COVID-19 advances, so does our understanding of its impact on the management of multiple sclerosis (MS). In this activity, originally delivered as a live webcast, Drs.
Pathways to Progress: Outlining Key Steps to Diagnosis and Evolving Therapeutic Approaches in CIDP
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
$0.00
Program DescriptionDespite recent advancements in chronic inflammatory demyelinating polyneuropathy (CIDP), significant challenges persist in its accurate diagnosis and optimal treatment. Throughout this program, Drs. Nicholas J. Silvestri, Christyn Edmundson, and Kelly G. Gwathmey will share their expertise, as they guide you through common electrodiagnostic and management pitfalls, outlining evidence-based approaches and drawing from their clinical experience with this rare disease.

Pages